Literature DB >> 31507311

Treatment Facility: An Important Prognostic Factor for Dedifferentiated Liposarcoma Survival.

Jonathan Michael Gootee1, Christina E Curtin1, Sarah J Aurit1, Saboor E Randhawa1, Bianca Y Kang1, Peter T Silberstein1.   

Abstract

A National Cancer Database study of on survival outcomes for patients with dedifferentiated liposarcomas found that insurance status, median household income, and treatment facility were associated with differences in median survival and 5- and 10-year survival probabilities.

Entities:  

Year:  2019        PMID： 31507311      PMCID： PMC6719806     

Source DB:  PubMed          Journal:  Fed Pract        ISSN： 1078-4497


  13 in total

Review 1.  Update on liposarcoma: a review for cytopathologists.

Authors:  Leslie G Dodd
Journal:  Diagn Cytopathol       Date:  2011-09-19       Impact factor: 1.582

2.  Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk.

Authors:  Kimberly Moore Dalal; Michael W Kattan; Cristina R Antonescu; Murray F Brennan; Samuel Singer
Journal:  Ann Surg       Date:  2006-09       Impact factor: 12.969

3.  Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis.

Authors:  Michael T Halpern; Elizabeth M Ward; Alexandre L Pavluck; Nicole M Schrag; John Bian; Amy Y Chen
Journal:  Lancet Oncol       Date:  2008-02-20       Impact factor: 41.316

4.  Impact of academic facility type and volume on post-surgical outcomes following diagnosis of glioblastoma.

Authors:  Alan Hauser; Sunil W Dutta; Timothy N Showalter; Jason P Sheehan; Surbhi Grover; Daniel M Trifiletti
Journal:  J Clin Neurosci       Date:  2017-11-04       Impact factor: 1.961

Review 5.  Well-differentiated and dedifferentiated liposarcomas.

Authors:  Jean-Michel Coindre; Florence Pédeutour; Alain Aurias
Journal:  Virchows Arch       Date:  2009-08-18       Impact factor: 4.064

Review 6.  Cancer disparities by race/ethnicity and socioeconomic status.

Authors:  Elizabeth Ward; Ahmedin Jemal; Vilma Cokkinides; Gopal K Singh; Cheryll Cardinez; Asma Ghafoor; Michael Thun
Journal:  CA Cancer J Clin       Date:  2004 Mar-Apr       Impact factor: 508.702

7.  Resectable well-differentiated versus dedifferentiated liposarcomas: two different diseases possibly requiring different treatment approaches.

Authors:  G Lahat; D A Anaya; X Wang; D Tuvin; D Lev; R E Pollock
Journal:  Ann Surg Oncol       Date:  2008-04-09       Impact factor: 5.344

8.  Comparison of facility type outcomes for oral cavity cancer: Analysis of the national cancer database.

Authors:  Samuel J Rubin; Michael B Cohen; Diana N Kirke; Muhammad M Qureshi; Minh Tam Truong; Scharukh Jalisi
Journal:  Laryngoscope       Date:  2017-07-03       Impact factor: 3.325

9.  Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard.

Authors:  J A Livingston; D Bugano; A Barbo; H Lin; J E Madewell; W L Wang; A J Lazar; W W Tseng; C L Roland; B W Feig; R Pollock; A P Conley; R S Benjamin; S Patel; N Somaiah
Journal:  Sci Rep       Date:  2017-09-19       Impact factor: 4.379

10.  Cancer survival disparities by health insurance status.

Authors:  Xiaoling Niu; Lisa M Roche; Karen S Pawlish; Kevin A Henry
Journal:  Cancer Med       Date:  2013-05-08       Impact factor: 4.452
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.